2026

（原著論文）

• Ampicillin/ceftriaxone vs. β-lactam/aminoglycoside combination therapy for Enterococcus faecalis infective endocarditis: a systematic review and meta-analysis.
  Sugimoto Y, Sasaki R, Tominaga M, Hirai R, Mihara T, Shimamura R, Yoshikawa M, Ikegami S, Shimada S, Tsubouchi A, Okamoto Y, Igarashi Y, Enoki Y, Taguchi K, Matsumoto K.
  Eur J Clin Microbiol Infect Dis. in press Abstract
• Comparative Efficacy and Safety of 15-Valent and 13-Valent Pneumococcal Conjugate Vaccines Alone and in Combination with the 23-Valent Polysaccharide Vaccine: A Systematic Review and Meta-analysis.
  Matsumoto Y, Mihara T, Okamoto Y, Tsubouchi A, Ikegami S, Takahashi M, Nakabayashi K, Nishimoto N, Mizukami Y, Muraishi T, Igarashi Y, Enoki Y, Taguchi K, Matsumoto K.
  Biol Pharm Bull. 2026; 49(7): 1073-1086. Abstract
• Three fluoroquinolones with different epithelial lining fluid penetration in a murine lung infection model: an experimental site-specific PK/PD study.
  Hosoi A, Duan S, Shimada S, Suzuki K, Mizukami Y, Shintani R, Takahashi M, Satake N, Muraishi T, Okamoto Y, Igarashi Y, Enoki Y, Taguchi K, Matsumoto K.
  Antimicrob Agents Chemother. 2026; 70(8): e0037526. Abstract
• Age and body weight-adjusted infusion rate (mg/kg/h) as risk factors for vancomycin infusion reaction in patients receiving perioperative antimicrobial prophylaxis: a retrospective cohort study.
  Iketani O, Uno S, Shinjoh M, Takemura R, Fukuda S, Seyama S, Kimura M, Ishikawa H, Hayakawa T, Uwamino Y, Namkoong H, Yoshifuji A, Obara H, Takano Y, Enoki Y, Taguchi K, Sato Y, Matsumoto K, Hasegawa N.
  JAC Antimicrob Resist. 2026; 8(3): dlag084. Abstract
• PCV13/PPSV23 Co-vaccination versus PPSV23 Monotherapy for the Prevention of Pneumococcal Infections: A Systematic Review and Meta-analysis.
  Matsumoto Y, Mihara T, Okamoto Y, Tsubouchi A, Ikegami S, Takahashi M, Nakabayashi K, Nishimoto N, Mizukami Y, Muraishi T, Igarashi Y, Enoki Y, Taguchi K, Matsumoto K.
  Biol Pharm Bull. 2026; 49(4): 666-682. Abstract
• Establishing an assay to evaluate d-amino acid oxidase enzyme kinetics and inhibition using WST-8 redox dye.
  Miyake K, Enoki Y, Nakazawa Y, Taguchi K, Matsumoto K.
  FEBS Open Bio. 2026; 16(9): 1645-1656. Abstract
• Impact of Chronic Kidney Disease on the Onset of Sepsis: A Systematic Review.
  Osa S, Enoki Y, Endo A, Kumamoto K, Kobayashi K, Komiya C, Satake N, Kawakami J, Yagi T, Taguchi K, Matsumoto K.
  Biol Pharm Bull. 2026; 49(1): 99-107. Abstract
• Secreted protein acidic and rich in cysteine-guided biomimetic delivery of nano-antioxidants reverses muscle atrophy in a mouse model of sarcopenia.
  Kanazawa G, Maeda H, Yasuda K, Noguchi I, Nishinoiri A, Taguchi K, Imoto S, Tsukigawa K, Yamasaki K, Sakuragi M, Ishima Y, Matsushita S, Nakamura T, Saruwatari J, Otagiri M, Watanabe H, Maruyama T.
  J Control Release. 2026; 391: 114567. Abstract
• Stepwise dual N-terminal modification of proteins via nickel(II)-mediated aldol and Pictet-Spengler reactions.
  Hanaya K, Morimi Y, Usui S, Taguchi K, Wada Y, Kawano M, Higashibayashi S, Sugai T.
  Tetrahedron Chem. 2026; 17: 100154. Abstract
• Application of epithelial lining fluid drug concentrations to MIC_i-Based PK/PD modeling of cefepime/nacubactam in a murine model of CPE pneumonia.
  Mizukami Y, Takahashi M, Suzuki K, Duan S, Ikegami S, Muraishi T, Satake N, Okamoto Y, Igarashi Y, Enoki Y, Taguchi K, Matsumoto K.
  J Infect Chemother. 2026; 32(1): 102889. Abstract
• Influence factors of metronidazole-related CNS disorders: an analysis of the Japan adverse drug event report and FDA adverse event reporting system.
  Takada K, Enoki Y, Samura M, Igarashi Y, Taguchi K, Tanikawa K, Matsumoto K.
  Expert Opin Drug Saf. 2026; 25(9): 1731-1737. Abstract

（総説論文）

• When Red Blood Cells Meet Carbon Monoxide: Yin and Yang in Medicines and Pharmaceuticals.
  Nagasaki T, Chuang VTG, Otagiri M, Taguchi K.
  Pharmaceuticals (Basel). 2026; 19(4): 634. Abstract

2025

（原著論文）

• Efficacy and safety of isavuconazole for invasive fungal infections: A systematic review and meta-analysis of randomized controlled trials.
  Kawasaki A, Shintani R, Takao R, Nakazawa Y, Mihara T, Ikegami S, Shimada S, Matsumoto Y, Okamoto Y, Igarashi Y, Enoki Y, Taguchi K, Matsumoto K.
  Med Mycol. 2025; 63(10): myaf089. Abstract
• Oral β-lactam combinations are effective in vitro against Mycobacterium avium, regardless of clarithromycin susceptibility.
  Yoshikawa M, Nishimura T, Misawa K, Shimamura R, Suzuki K, Kashimura S, Igarashi Y, Enoki Y, Taguchi K, Hasegawa N, Namkoong H, Matsumoto K.
  Microbiol Spectr. 2025; 13(11): e0201225. Abstract
• Prediction of treatment success in patients with Enterococcus faecium bacteremia using vancomycin AUC₂₄/MIC ratio: A multicenter retrospective study.
  Hanai Y, Matsumoto K, Hanawa K, Endo A, Hashi H, Miyazaki T, Yamaguchi T, Harada S, Yokoo T, Uekusa S, Yokoyama Y, Maruyama R, Tsujimura S, Asakawa D, Namiki T, Isoda R, Enoki Y, Taguchi K, Matsuo K.
  Diagn Microbiol Infect Dis. 2025; 113(2): 116961. Abstract
• Risk stratification of AUC upward deviation in patients with low serum creatinine levels treated with vancomycin: a multicenter retrospective study.
  Ishigo T, Suzuki A, Ibe Y, Fujii S, Fukudo M, Yoshida H, Tanaka H, Fujihara H, Yamaguchi F, Ebihara F, Maruyama T, Hamada Y, Samura M, Nagumo F, Komatsu T, Tomizawa A, Takuma A, Chiba H, Nishi Y, Enoki Y, Taguchi K, Matsumoto K.
  J Pharm Pharmacol. 2025; 77(9): 1255-1263. Abstract
• CKD-Induced Oxidative Twitch Muscle Atrophy Is Mediated by TGF- β.
  Homma K, Enoki Y, Taguchi K, Matsumoto K.
  Kidney360. 2025; 6(9): 1438-1447. Abstract
• Establishment and validation of downsized hollow-fibre infection model and pharmacokinetics/pharmacodynamics analysis of VAN on Enterococcus faecium.
  Hayashi Y, Takahashi M, Sasaki M, Suzuki K, Mizukami Y, Liu X, Enoki Y, Taguchi K, Yamaguchi T, Tateda K, Matsumoto K.
  J Antimicrob Chemother. 2025; 80(8): 2092-2099. Abstract
• Shortening the interval between the first and the second dose of vancomycin facilitates rapid achievement of the target AUC without increasing the risk of acute kidney injury, provided the AUC on the second day is appropriately controlled: a multicenter retrospective study.
  Ishigo T, Suzuki A, Ibe Y, Fujii S, Fukudo M, Yoshida H, Tanaka H, Fujihara H, Yamaguchi F, Ebihara F, Maruyama T, Hamada Y, Yagi Y, Samura M, Nagumo F, Komatsu T, Tomizawa A, Takuma A, Chiba H, Nishi Y, Enoki Y, Taguchi K, Matsumoto K.
  J Pharm Health Care Sci. 2025; 11(1): 44. Abstract
• Methemoglobin-Encapsulating Liposome: A Low-Risk Intravascular Contrast Agent for Magnetic Resonance Imaging.
  Taguchi K, Sumiyoshi A, Suzuki Y, Ozawa Y, Iiyama M, Gao S, Sakai H, Osada K, Matsumoto K, Aoki I.
  ACS Appl Bio Mater. 2025; 8(4): 2838-2846. Abstract
• Development and validation of a population pharmacokinetic model of vancomycin for patients of advanced age.
  Takada K, Samura M, Igarashi Y, Suzuki A, Ishigo T, Fujii S, Ibe Y, Yoshida H, Tanaka H, Ebihara F, Maruyama T, Hamada Y, Komatsu T, Tomizawa A, Takuma A, Chiba H, Yagi Y, Nishi Y, Enoki Y, Taguchi K, Tanikawa K, Kunishima H, Matsumoto K.
  J Pharm Health Care Sci. 2025; 11(1): 18. Abstract
• Combined dual β-lactams and diazabicyclooctane β-lactamase inhibitor is highly effective against Mycobacterium abscessus species in vitro.
  Misawa K, Nishimura T, Yoshikawa M, Shimamura R, Kashimura S, Enoki Y, Taguchi K, Matsumoto K, Hasegawa N.
  J Glob Antimicrob Resist. 2025; 42: 142-150. Abstract
• Carbon monoxide alleviates endotoxin-induced acute lung injury via NADPH oxidase inhibition in macrophages and neutrophils.
  Watabe Y, Giam Chuang VT, Sakai H, Ito C, Enoki Y, Kohno M, Otagiri M, Matsumoto K, Taguchi K.
  Biochem Pharmacol. 2025; 233: 116782. Abstract
• Treatment success prediction in patients with methicillin-resistant coagulase-negative staphylococci infections, using vancomycin AUC24/MIC ratio: a multicentre retrospective cohort study.
  Hanai Y, Matsumoto K, Endo A, Hanawa K, Hashi H, Miyazaki T, Yamaguchi T, Harada S, Yokoo T, Uekusa S, Asakawa D, Yokoyama Y, Maruyama R, Tsujimura S, Namiki T, Isoda R, Enoki Y, Taguchi K, Matsuo K.
  J Antimicrob Chemother. 2025; 80(2): 538-546. Abstract
• Simulated achievement rate of β-lactams/nacubactam treatment in humans using instantaneous MIC-based PK/PD analysis.
  Igarashi Y, Taguchi K, Enoki Y, Chuang VTG, Matsumoto K.
  J Antimicrob Chemother. 2025; 80(2): 547-553. Abstract
• One-Step Maleimide-Based Dual Functionalization of Protein N-Termini.
  Hanaya K, Taguchi K, Wada Y, Kawano M.
  Angew Chem Int Ed Engl. 2025; 64(5): e202417134. Abstract
• Development of a pharmacokinetic/pharmacodynamic evaluation model for osteomyelitis and usefulness of tedizolid as an alternative to vancomycin against MRSA osteomyelitis.
  Liu X, Enoki Y, Taguchi K, Matsumoto K.
  J Pharm Pharmacol. 2025; 77(2): 291-298. Abstract
• SARS-CoV-2 mRNA vaccine-related myocarditis and pericarditis: An analysis of the Japanese Adverse Drug Event Report database.
  Takada K, Taguchi K, Samura M, Igarashi Y, Okamoto Y, Enoki Y, Tanikawa K, Matsumoto K.
  J Infect Chemother. 2025; 31(1): 102485. Abstract
• Direct comparison of the effects of first- and second-generation H₁ -receptor blockers on motor functions in mice.
  Taguchi K, Tenjin K, Sakamoto Y, Shimada A, Hara R, Iketani O, Okamoto Y, Enoki Y, Kizu J, Hori S, Matsumoto K.
  Pharmazie. 2025; 80(1): 24-28. Abstract
• 医療用一般用共用医薬品（仮称）の創設提言に対する薬剤師の認知および見解に関する実態把握調査
  岡本 侑子, 田口 和明, 榎木 裕紀, 堀 里子, 山浦 克典, 松元 一明
  医療薬学, 2025; 51(4): 196-202 Abstract

2024年以前の論文・総説

（原著論文）

• Suzuki Y, Yamada T, Enoki Y, Matsumoto K, Komatsu T, Taguchi K.
  Hydrosulphide-methaemoglobin-albumin cluster: a hydrogen sulphide donor.
  J Mater Chem B. 12(44): 11515-11522. (2024)
• Suzuki A, Samura M, Ishigo T, Fujii S, Ibe Y, Yoshida H, Tanaka H, Ebihara F, Maruyama T, Hamada Y, Fujihara H, Yamaguchi F, Nagumo F, Komatsu T, Tomizawa A, Takuma A, Chiba H, Nishi Y, Enoki Y, Taguchi K, Matsumoto K.
  Identification of Patients Who Require Two-Point Blood Sampling for the Peak and Trough Values Rather Than One-Point Blood Sampling for the Trough Value for the Evaluation of AUC of Vancomycin Using Bayesian Estimation.
  Pharm Res. 41(11):2161-2171. (2024)
• Hara R, Taguchi K, Ogino H, Okamoto Y, Enoki Y, Kizu J, Hori S, Matsumoto K.
  Investigating the hypothermic effects of fluoroquinolone antimicrobials on non-bacterial fever model mice.
  J Pharm Health Care Sci. 10(1): 68. (2024)
• Osa S, Enoki Y, Takahashi D, Chuang VTG, Taguchi K, Matsumoto K.
  Enhancement of T-cell immunosuppression in sepsis augmented by sciatic denervation-induced skeletal muscle atrophy.
  FEBS Lett. 598(20): 2581-2591. (2024)
• Taguchi K, Hashimoto M, Tokuno M, Takeoka S, Maruyama T, Yamasaki K, Otagiri M.
  Qualitative and quantitative status of cytochrome P450s after the administration of a liposomal platelet substitute in rat liver.
  Xenobiotica. 54(9): 624-628. (2024)
• Yanagisawa H, Maeda H, Noguchi I, Tanaka M, Wada N, Nagasaki T, Kobayashi K, Kanazawa G, Taguchi K, Chuang VTG, Sakai H, Nakashima H, Kinoshita M, Kitagishi H, Iwakiri Y, Sasaki Y, Otagiri M, Watanabe H, Maruyama T.
  Carbon monoxide-loaded red blood cells ameliorate nonalcoholic steatohepatitis progression via enhancing AMP-activated protein kinase activity and inhibiting Kupffer cell activation.
  Redox Biol. 76: 103314. (2024)
• Nakamura K, Matsumoto K, Enoki Y, Taguchi K, Yamashita S, Kai J, Hayashi H.
  Antimicrobial stewardship of oral third-generation cephalosporins in community pharmacy: A single-center quasi-experimental study.
  Bio Pharm Bull. 47(8): 1447-1451. (2024)
• Hanai Y, Hashi H, Hanawa K, Endo A, Miyazaki T, Yamaguchi T, Harada S, Yokoo T, Uekusa S, Namiki T, Yokoyama Y, Asakawa D, Isoda R, Enoki Y, Taguchi K, Matsumoto K, Matsuo K.
  Predictive value of vancomycin AUC₂₄/MIC ratio for 30-day mortality in patients with severe or complicated methicillin-resistant Staphylococcus aureus infections: A multicenter retrospective study.
  Pharm Res. 41: 1381-1389. (2024)
• Ito C, Taguchi K, Yamada T, Hanaya K, Enoki Y, Sugai T, Komatsu T, Matsumoto K.
  Dual delivery of carbon monoxide and doxorubicin using haemoglobin-albumin cluster: Proof of concept for well-tolerated cancer therapy.
  J Mater Chem B. 12: 5600-5608. (2024)
• Noguchi I, Maeda H, Kobayshi K, Nagasaki T, Kato H, Yanagisawa H, Wada N, Kanazawa G, Kaji T, Sakai H, Fujimaki S, Ono Y, Taguchi K, Chuang VTG, Saruwatari J, Otagiri M, Watanabe H, Maruyama T.
  Carbon monoxide-loaded cell therapy as an exercise mimetic for sarcopenia treatment.
  Free Radic Biol Med. 220: 67-77. (2024)
• Taguchi K, Chuang VTG, Ozawa M, Sakamoto Y, Hara R, Iketani O, Enoki Y, Kizu J, Hori S, Matsumoto K.
  Anti-edematous effects of epinastine, cetirizine and its enantiomers in λ-carrageenan-induced edema in rat hind paw.
  Pharmazie. 6: 98-100. (2024)
• Ishigo T, Matsumoto K, Yoshida H, Tanaka H, Ibe Y, Fujii S, Fukudo M, Fujihara H, Yamaguchi F, Ebihara F, Maruyama T, Hamada Y, Samura M, Nagumo F, Komatsu T, Tomizawa A, Takuma A, Chiba H, Nishi Y, Enoki Y, Taguchi K, Suzuki A.
  Relationship between nephrotoxicity and area under the concentration-time curve of vancomycin in critically ill patients: a multicenter retrospective study.
  Microbiol Spectr. 12(7): e0373923. (2024)
• Taguchi K, Ogaki S, Maeda H, Ishima Y, Watanabe H, Otagiri M, Maruyama T.
  Carbon monoxide alleviates post-ischemia-reperfusion skeletal muscle injury and systemic inflammation.
  Bio Pharm Bull. 47(4): 868-871. (2024)
• Taguchi K, Chuang VTG, Ogino H, Hara R, Iketani O, Enoki Y, Kizu J, Hori S, Matsumoto K.
  Direct comparison of anti-inflammatory effects of 14-, 15-, and 16-membered macrolide antibiotics in experimental inflammation model induced by carrageenan in rats.
  Pharmazie. 3-5: 64-66. (2024)
• Enoki Y, Kanezaki Y, Takahata I, Taguchi K, Matsumoto K.
  Betulinic acid ameliorates cast-immobilized skeletal muscle atrophy but not denervation-induced skeletal muscle atrophy.
  JCSM Rapid Communications. 7: 30-39. (2024)
• Hasegawa T, Tsukigawa K, Commey K, Sakuragi M, Imoto S, Taguchi K, Nishi K, Otagiri M, Yamasaki K.
  Preparation and in vitro characterization of fatty-acid modified pirarubicin nanosuspensions stabilized by albumin.
  Chem Pharm Bull. 72(1): 21-27. (2024)
• Ishigo T, Fujii S, Ibe Y, Aigami T, Nakano K, Fukudo M, Yoshida H, Tanaka H, Ebihara F, Maruyama T, Hamada Y, Suzuki A, Fujihara H, Yamaguchi F, Samura M, Nagumo F, Komatsu T, Tomizawa A, Takuma A, Chiba H, Nishi Y, Enoki Y, Taguchi K, Matsumoto K.
  Flowchart for predicting achieving the target area under the concentration-time curve of vancomycin in critically ill Japanese patients: A multicenter retrospective study.
  J Infect Chemother. 30(4): 329-336. (2024)
• Yamada T, Ishimaru M, Shoji T, Tomiyasu H, Tochinai R, Taguchi K, Komatsu T.
  Polyoxazoline-conjugated l-asparaginase: An antibody-production-free therapeutic agent for acute lymphoblastic leukemia.
  ACS Appl Bio Mater. 6(12): 5789-5797. (2023)
• Itagaki M, Iketani O, Enoki Y, Chuang VTG, Taguchi K, Uno S, Uchida S, Namkoong H, Uwamino Y, Takano Y, Hasegawa N, Matsumoto K.
  Analysis of risk factors for developing tuberculosis in patients who received prophylactic latent tuberculosis infection treatment with experience of biologic medications.
  Biol Pharm Bull. 46(12): 1832-1837. (2023)
• Suzuki Y, Arakida Y, Sakai H, Enoki Y, Matsumoto K, Taguchi K. Elucidating the binding properties of methemoglobin in red blood cell to cyanide, hydrosulfide, and azide ions using artificial red blood cell.
  Toxicol Appl Pharmacol. 481: 116752. (2023)
• Tanaka Y, Tashiro S, Ikegami S, Enoki Y, Taguchi K, Matsumoto K.
  Oral teicoplanin administration suppresses recurrence of Clostridioides difficile infection: Proof of concept.
  Anaerobe. 84: 102789. (2023)
• Ito M, Liu X, Taguchi K, Enoki Y, Kuroda Y, Kizu J, Matsumoto K.
  Anti-inflammatory actions of expectorants in a rat carrageenan-induced footpad edema model.
  Pharmazie. 78(6-7): 86-88. (2023)
• Homma K, Enoki Y, Uchida S, Taguchi K, Matsumoto K.
  A combination of 5/6-nephrectomy and unilateral ureteral obstruction model accelerates progression of remote organ fibrosis in chronic kidney disease.
  FASEB Bioadv. 5(10): 377-394. (2023)
• Igarashi Y, Takemura W, Liu X, Kojima N, Morita T, Chuang VTG, Enoki Y, Taguchi K, Matsumoto K.
  In vivo pharmacokinetic/pharmacodynamic analysis of the efficacy of the cefepime/nacubactam combination against β-Lactamase-producing Enterobacterales based on the instantaneous MIC concept.
  Pharm Res. 40(10): 2423-2431. (2023)
• Nagasaki T, Maeda H, Yanagisawa H, Nishida K, Kobayashi K, Wada N, Noguchi I, Iwakiri R, Taguchi K, Sakai H, Saruwatari J, Watanabe H, Otagiri M, Maruyama T.
  Carbon monoxide-loaded red blood cell prevents the onset of cisplatin-induced acute kidney injury.
  Antioxidants (Basel). 12(9): 1705. (2023)
• Suzuki Y, Taguchi K, Okamoto W, Enoki Y, Komatsu T, Matsumoto K. Pharmaceutical stability of methemoglobin-albumin cluster as an antidote for hydrogen sulfide poisoning after one-year storage in freeze-dried form.
  Int J Pharm. 645: 123433. (2023)
• Hu M, Taguchi K, Matsumoto K, Kobatake E, Ito Y, Ueda M.
  Polysarcosine-coated liposomes attenuating immune response induction and prolonging blood circulation.
  J Colloid Interface Sci. 651: 273-283. (2023)
• Isobe N, Chuang VTG, Liu X, Enoki Y, Taguchi K, Matsumoto K.
  The anti-inflammatory effect of tedizolid on carrageenan-induced footpad edema rat model.
  J Infect Chemother. 29(11): 1088-1090. (2023)
• Suzuki Y, Taguchi K, Okamoto W, Enoki Y, Komatsu T, Matsumoto K.
  Pharmaceutical integrity of lyophilized methemoglobin-albumin clusters after reconstitution.
  ACS Omega. 8(25): 22589-22595. (2023)
• Okamoto W, Usui T, Hasegawa M, Kobayashi T, Fujisawa J, Taguchi K, Matsumoto K, Kohno M, Iwazaki M, Shimano S, Nagao I, Toyoda H, Matsumura N, Tomiyasu H, Tochinai R, Komatsu T.
  Polyoxazoline-conjugated porcine serum albumin as an artificial plasma expander for dogs.
  Sci Rep. 13(1): 9512. (2023)
• Igarashi Y, Kojima N, Takemura W, Liu X, Morita T, Mizukami Y, Enoki Y, Taguchi K, Yokoyama Y, Nakamura T, Matsumoto K.
  In vivo pharmacokinetics/pharmacodynamics profiles for appropriate doses of cefditoren pivoxil against pneumoniae in murine lung-infection model.
  Pharm Res. 40(7): 1789-1797. (2023)
• Tashiro S, Taguchi K, Enoki Y, Matsumoto K.
  Antimicrobial efficacy evaluations of metronidazole against Clostridioides difficile infection using fecal pharmacokinetic and pharmacodynamic analyses.
  Pharm Res. 40(7): 1799-1806. (2023)
• Tashiro S, Mihara T, Okawa R, Tanaka Y, Samura M, Enoki Y, Taguchi K, Matsumoto K, Yamagishi Y.
  Optimal therapeutic recommendation for Clostridioides difficile infection in pediatric and adolescent populations: a systematic review and meta-analysis.
  Eur J Pediatr. 182(6): 2673-2681. (2023)
• Suzuki Y, Taguchi K, Okamoto W, Enoki Y, Komatsu T, Matsumoto K.
  Methemoglobin-albumin clusters for cyanide detoxification.
  Toxicol Appl Pharmacol. 466: 116472. (2023)
• Igarashi Y, Takemura W, Liu X, Kojima N, Morita T, Chuang VTG, Enoki Y, Taguchi K, Matsumoto K.
  Development of an optimized and practical pharmacokinetics/pharmacodynamics analysis method for aztreonam/nacubactam against carbapenemase-producing pneumoniae.
  J Antimicrob Chemother. 78(4): 991-999. (2023)
• Samura M, Takada K, Hirose N, Kurata T, Nagumo F, Uchida M, Inoue J, Tanikawa K, Enoki Y, Taguchi K, Matsumoto K, Ueda T, Fujimura S, Mikamo H, Takesue Y, Mitsutake K.
  Comparison of the efficacy and safety of standard- and high-dose daptomycin: A systematic review and meta-analysis.
  Br J Clin Pharmacol. 89(4): 1291-1303. (2023)
• Tashiro S, Taguchi K, Enoki Y, Matsumoto K.
  Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models.
  Clin Microbiol Infect. 29(5): 616-622. (2023)
• Enoki Y, Nagai T, Hamamura Y, Osa S, Nakamura H, Taguchi K, Watanabe H, Maruyama T, Matsumoto K.
  The G protein-coupled receptor ligand apelin-13 ameliorates skeletal muscle atrophy induced by chronic kidney disease.
  J Cachexia Sarcopenia Muscle. 14(1): 553-564. (2023)
• Osa S, Enoki Y, Miyajima T, Akiyama M, Fujiwara Y, Taguchi K, Kim YG, Matsumoto K.
  Sciatic denervation-induced skeletal muscle atrophy is associated with persistent inflammation and increased mortality during sepsis.
  Shock. 59(3): 417-425. (2023)
• Liu X, Tashiro S, Igarashi Y, Takemura W, Kojima N, Morita T, Hayashi M, Enoki Y, Taguchi K, Matsumoto K.
  Differences in pharmacokinetic/pharmacodynamic parameters of tedizolid against VRE and MRSA.
  Pharm Res. 40(1): 187-196. (2023)
• Liu X, Aoki M, Osa S, Ito C, Saiki R, Nagai T, Enoki Y, Taguchi K, Matsumoto K.
  Safety of linezolid in patients with decreased renal function and trough monitoring: a systematic review and meta-analysis.
  BMC Pharmacol Toxicol. 23(1): 89. (2022)
• Suzuki Y, Taguchi K, Okamoto W, Enoki Y, Komatsu T, Matsumoto K.
  Methemoglobin-albumin clusters for the treatment of hydrogen sulfide intoxication.
  J Control Release. 349: 304-314. (2022)
• Nagasaki T, Maeda H, Taguchi K, Yanagisawa H, Nishida K, Kobayashi K, Wada N, Noguchi I, Murata R, Sakai H, Kitagishi H, Saruwatari J, Watanabe H, Otagiri M, Maruyama T.
  A bioinspired carbon monoxide delivery system prevents acute kidney injury and the progression to chronic kidney disease.
  Redox Biol. 54: 102371. (2022)
• Taguchi K, Suzuki Y, Tsutsuura M, Hiraoka K, Watabe Y, Enoki Y, Otagiri M, Sakai H, Matsumoto K.
  Liposomal artificial red blood cell-based carbon monoxide donor is a potent renoprotectant against cisplatin-induced acute kidney injury.
  Pharmaceutics. 14(1): 57. (2022)
• Watabe Y, Taguchi K, Sakai H, Enoki Y, Maruyama T, Otagiri M, Kohno M, Matsumoto K.
  Bioinspired carbon monoxide delivery using artificial blood attenuates the progression of obliterative bronchiolitis via suppression of macrophage activation by IL-17A.
  Eur J Pharm Biopharm. 170: 43-51. (2022)
• Suzuki Y, Taguchi K, Hanyu S, Kure T, Enoki Y, Otagiri M, Sakai H, Matsumoto K.
  Oxidized liposomal artificial red blood cells rescue azide-poisoned mice from lethal toxidrome by recovering cytochrome c oxidase activity.
  J Drug Deliv Sci Technol. 71: 103282. (2022)
• Suzuki Y, Taguchi K, Kure T, Enoki Y, Otagiri M, Sakai H, Matsumoto K.
  Liposomal methemoglobin as a potent antidote for hydrogen sulfide poisoning.
  Toxicol Appl Pharmacol. 450: 116159. (2022)
• Ito C, Taguchi K, Moroi Y, Enoki Y, Tokuda R, Yamasaki K, Imoto S, Matsumoto K.
  Trimethoxy trityl groups as a potent substituent for anti-cancer cytidine analog prodrugs.
  J Pharm Sci. 111(8): 2201-2209. (2022)
• Taguchi K, Hayashi Y, Ohuchi M, Yamada H, Yagishita S, Enoki Y, Matsumoto K, Hamada A.
  Augmented clearance of nivolumab is associated with renal functions in chronic renal disease model rats.
  Drug Metab Dispos. 50(6): 822-826. (2022)
• Misawa K, Nishimura T, Kashimura S, Enoki Y, Taguchi K, Uno S, Uwamino Y, Matsumoto K, Hasegawa N.
  In vitro effects of diazabicyclooctane β-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus
  Int J Antimicrob Agents. 60(5-6): 106669. (2022)
• Ichinose N, Shinoda K, Yoshikawa G, Fukao E, Enoki Y, Taguchi K, Oda T, Tsutsumi K, Matsumoto K.
  Exploring the factors affecting the transferability of vancomycin to cerebrospinal fluid in postoperative neurosurgical patients with bacterial meningitis.
  Biol Pharm Bull. 45(9): 1398-1402. (2022)
• Yamasaki K, Sakurama K, Nishi K, Tsukigawa K, Seo H, Otagiri M, Taguchi K.
  An in vitro comparative study of the binding of caspofungin and micafungin to plasma proteins.
  J Pharm Pharmacol. 74(1): 88-93. (2022)
• Ichinose N, Yoshikawa G, Fukao E, Takahata T, Ichisawa M, Enoki Y, Taguchi K, Oda T, Tsutsumi K, Matsumoto K.
  Influences of protein levels on the cerebrospinal fluid distribution of ceftazidime & ceftriaxone in the cerebrospinal fluid of patients with inflamed meningitis.
  J Infect Chemother. 28: 1216-1219. (2022)
• Hasegawa T, Tashiro S, Mihara T, Kon J, Sakurai K, Tanaka Y, Morita T, Enoki Y, Taguchi K, Matsumoto K, Nakajima K, Takesue Y.
  Efficacy of surgical skin preparation with chlorhexidine in alcohol according to the concentration required to prevent surgical site infection: A systematic review and meta-analysis.
  BJS Open. 6(5): zrac111. (2022)
• Hanaya K, Yamoto K, Taguchi K, Matsumoto K, Higashibayashi S, Sugai T.
  Single-step N-terminal modification of proteins via a bio-inspired copper (II)-mediated aldol reaction.
  Chemistry. 28(47): e202201677. (2022)
• Samura M, Takada K, Hirose N, Kurata T, Nagumo F, Koshioka S, Ishii J, Uchida M, Inoue J, Enoki Y, Taguchi K, Tanikawa K, Matsumoto K. Incidence of elevated creatine phosphokinase between daptomycin alone and concomitant daptomycin and statins: a systematic review and meta-analysis.
  Br J Clin Pharmacol. 88(5): 1985-1998. (2022)
• Yamasaki K, Fujisaki-Hirakawa M, Taguchi K, Kadowaki D, Tsukigawa K, Nishi K, Otagiri M, Seo H.
  In vitro and in vivo assessment of Atemoya fruit (Annona atemoya) for food-drug interaction.
  Eur J Drug Metab Pharmacokinet. 47(2): 177-185. (2022)
• Tashiro S, Mihara T, Sasaki M, Shimamura C, Shimamura R, Suzuki S, Yoshikawa M, Hasegawa T, Enoki Y, Taguchi K, Matsumoto K, Ohge H, Suzuki H, Nakamura A, Mori N, Morinaga Y, Yamagishi Y, Yoshizawa S, Yanagihara K, Mikamo H, Kunishima H.
  Oral fidaxomicin versus vancomycin for the treatment of Clostridioides difficile infection: A systematic review and meta-analysis of randomized controlled trials.
  J Infect Chemother. 28(11): 1536-1545. (2022)
• Toda M, Yoshifuji A, Hosoya K, Taguchi K, Komatsu M, Kobayashi E, Fujii K, Kato A, Hasegawa N, Matsumoto K, Ryuzaki M.
  Ceftazidime encephalopathy developed without the elevation of cerebrospinal fluid concentration of ceftazidime: A case report of two cases.
  J Infect Chemother. 28(12): 1667-1671. (2022)
• Iketani O, Komeya A, Enoki Y, Taguchi K, Uno S, Uwamino Y, Matsumoto K, Kizu J, Hasegawa N.
  Impact of rifampicin on the pharmacokinetics of clarithromycin and 14-hydroxy clarithromycin in patients with multidrug combination therapy for pulmonary Mycobacterium avium complex infection.
  J Infect Chemother. 28: 61-66. (2022)
• Samura M, Kitahiro Y, Tashiro S, Moriyama H, Hamamura Y, Takahata I, Kawabe R, Enoki Y, Taguchi K, Takesue Y, Matsumoto K.
  Efficacy and safety of daptomycin versus vancomycin for bacteremia caused by Methicillin-Resistant Staphylococcus aureus with vancomycin minimum inhibitory concentration > 1 µg/mL: A systematic review and meta-analysis.
  Pharmaceutics. 14(4): 714. (2022)
• Gotoda M, Enoki Y, Shishido S, Taguchi K, Matsumoto K.
  Neurotoxicity associated with colistin methanesulfonate treatment is enhanced by concomitant sevoflurane inhalation.
  Toxicology Reports. 9: 1255-1260. (2022)
• Ozawa T, Namkoong H, Takaya R, Takahashi Y, Fukunaga K, Enoki Y, Taguchi K, Kizu J, Matsumoto K, Hasegawa N.
  Analysis of adverse drug events in pulmonary Mycobacterium avium complex disease using spontaneous reporting system.
  BMC Infect Dis. 22: 580. (2022)
• 田口和明, 榎木裕紀, 堀里子, 山浦克典, 松元一明.
  人口動態統計に基づいたセルフメディケーション税制に関する実態調査と課題抽出.
  医療薬学, 48(7): 276-283. (2022)
• Suzuki Y, Taguchi K, Kure T, Sakai H, Enoki Y, Otagiri M, Matsumoto K.
  Liposome-encapsulated methemoglobin as an antidote against cyanide poisoning.
  J Control Release. 337: 59-70. (2021)
• Suzuki Y, Taguchi K, Kure T, Enoki Y, Otagiri M, Sakai H, Matsumoto K.
  Long-term pharmaceutical stability of liposome-encapsulated methemoglobin as an antidote for cyanide poisoning.
  Int J Pharm. 610: 121260. (2021)
• Hashimoto M, Taguchi K, Imoto S, Yamasaki K, Mitsuya H, Otagiri M.
  Pharmacokinetics of 4′-cyano-2′-deoxyguanosine, a novel nucleoside analog inhibitor of the resistant hepatitis B virus, in a rat model of chronic kidney disease.
  J Infect Chemother. 27: 702-706. (2021)
• Tashiro S, Hayashi M, Takemura W, Igarashi Y, Liu X, Mizukami Y, Kojima N, Enoki Y, Taguchi K, Yokoyama Y, Nakamura T, Matsumoto K. Pharmacokinetics/pharmacodynamics evaluation of flomoxef against Extended-spectrum beta-lactamase-producing Escherichia coli in vitro and in vivo in a murine thigh infection model.
  Pharm Res. 38(1): 27-35. (2021)
• Takemura W, Tashiro S, Hayashi M, Igarashi Y, Liu X, Mizukami Y, Kojima N, Morita T, Enoki Y, Taguchi K, Yokoyama Y, Nakamura T, Matsumoto K.
  Cefmetazole as an alternative to carbapenems against extended-spectrum beta-lactamase-producing Escherichia coli infections based on in vitro and in vivo pharmacokinetics/pharmacodynamics experiments.
  Pharm Res. 38: 1839-1846. (2021)
• Ichinose N, Yoshikawa G, Fukao E, Ichisawa M, Takahata T, Enoki Y, Taguchi K, Oda T, Tsutsumi K, Matsumoto K.
  Different intra-cerebrospinal distribution of linezolid in patients with inflammatory meningitis.
  Int J Infect Dis. 110: 382-384. (2021)
• Enoki Y, Kishi N, Sakamoto K, Uchiyama E, Hayashi Y, Suzuki N, Ito M, Taguchi K, Yokoyama Y, Kizu J, Matsumoto K.
  Multivalent cation and polycation polymer preparations influence pharmacokinetics of dolutegravir via chelation-type drug interactions.
  Drug Metab Pharmacokinet. 37: 100371. (2021)
• Sakamoto Y, Isono H, Enoki Y, Taguchi K, Miyazaki T, Kunimoto H, Koike H, Hagihara M, Matsumoto K, Nakajima H, Sahashi Y, Matsumoto K. Population pharmacokinetic analysis and dosing optimization of fluconazole prophylaxis in hematological malignancy patients.
  J Fungi. 7(11): 975. (2021)
• Misawa K, Iketani O, Enoki Y, Taguchi K, Uno S, Uwamino Y, Hasegawa N, Matsumoto K.
  Retrospective study of the efficacy and safety of metronidazole and vancomycin for Clostridioides difficile
  J Infect Chemother. 27: 1407-1412. (2021)
• Samura M, Hirose N, Kurata T, Takada K, Nagumo F, Koshioka S, Ishii J, Uchida M, Inoue J, Enoki Y, Taguchi K, Higashita R, Kunika N, Tanikawa K, Matsumoto K.
  Identification of risk factors for daptomycin-associated creatine phosphokinase elevation and development of a risk prediction model for incidence probability.
  Open Forum Infect Dis. 8(12): ofab568. (2021)
• Sakamoto Y, Kawabe K, Suzuki T, Sano K, Ide K, Nishigaki T, Enoki Y, Taguchi K, Koike H, Kato H, Sahashi Y, Matsumoto K.
  Species distribution of candidemia and their susceptibility in a single Japanese university hospital: Prior micafungin use affects the appearance of candida parapsilosis and elevation of micafungin MICs in Non-parapsilosis candida species.
  J Fungi. 7(8): 596. (2021)
• Samura M, Takada K, Yamamoto R, Ito H, Nagumo F, Uchida M, Kurata T, Koshioka S, Enoki Y, Taguchi K, Higashita R, Kunika N, Tanikawa K, Matsumoto K.
  Population pharmacokinetic analysis and dosing optimization based on unbound daptomycin concentration and cystatin C in nonobese elderly patients with hypoalbuminemia and chronic kidney disease.
  Pharm Res. 38(6): 1041-1055. (2021)
• Moriyama H, Tsutsuura M, Kojima N, Mizukami Y, Tashiro S, Osa S, Enoki Y, Taguchi K, Oda K, Fujii S, Takahashi Y, Hamada Y, Kimura T, Takesue Y, Matsumoto K.
  The optimal trough-guided monitoring of vancomycin in children: Systematic review and meta-analyses.
  J Infect Chemother. 27: 781-785. (2021)
• Tsutsuura M, Moriyama H, Kojima N, Mizukami Y, Tashiro S, Osa S, Enoki Y, Taguchi K, Oda K, Fujii S, Takahashi Y, Hamada Y, Kimura T, Takesue Y, Matsumoto K.
  The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing.
  BMC Infect Dis. 21(1): 153. (2021)
• Yamasaki K, Nishi K, Tsukigawa K, Taguchi K, Otagiri M, Seo H.
  Possible role of electrolytes on the formation of precipitates during the infusion of nafamostat mesilate in hemodialysis.
  Biol Pharm Bull. 44(2): 259-265. (2021)
• Ohuchi M, Yagishita S, Taguchi K, Goto Y, Fukahori M, Enoki Y, Shimada T, Yamaguchi M, Matsumoto K, Hamada A.
  Use of an alternative signature peptide during development of a LC-MS/MS assay of plasma nivolumab levels applicable for multiple species.
  J Chromatogr B Analyt Technol Biomed Life Sci. 1162: 122489. (2021)
• Enoki Y, Igarashi Y, Watabe Y, Honma K, Suzuki Y, Hayashi Y, Hiraoka K, Taguchi K, Matsumoto K.
  Remdesivir for the treatment of coronavirus COVID-19: A meta-analysis of randomised controlled trials.
  J Glob Antimicrob Resist. 24: 81-82. (2021)
• Kuroda T, Minamijima Y, Niwa H, Tamura N, Mita H, Fukuda K, Kaimachi M, Suzuki Y, Enoki Y, Taguchi K, Matsumoto K, Toutain PL, Bousquet-Melou A, Kasashima Y.
  Rational dosage regimens for cephalothin and cefazolin using pharmacokinetics and pharmacodynamics analysis in healthy horses.
  Equine Vet J. 53(6): 1239-1249. (2021)
• 田口和明, 榎木裕紀, 有賀聡美, 榊原幹夫, 堀里子, 山浦克典, 松元一明.
  セルフメディケーション税制に対する新人薬局薬剤師の認知・見解実態把握調査.
  医療薬学, 47(7): 358-363. (2021)
• 田口和明, 榎木裕紀, 有賀聡美, 榊原幹夫, 堀里子, 山浦克典, 松元一明.
  健康セミナー参加者におけるセルフメディケーション税制に関する実態調査と税制改定に向けた課題の抽出.
  医療薬学, 47(5): 256-263. (2021)
• 山田聖浩, 棚橋美里, 山﨑啓之, 田口和明, 平山文俊, 瀬尾量, 森岡淳子.
  院内製剤酢酸含有軟膏の保存安定性評価.
  医療薬学, 47(3): 171-177. (2021)
• Taguchi K, Ogaki S, Nagasaki T, Yanagisawa H, Nishida K, Maeda H, Enoki Y, Matsumoto K, Sekijima H, Ooi K, Ishima Y, Watanabe H, Fukagawa M, Otagiri M, Maruyama T.
  Carbon monoxide rescues the developmental lethality of experimental rat models of rhabdomyolysis-induced acute kidney injury.
  J Pharmacol Exp Ther. 372(3): 355-365. (2020)
• Taguchi K, Chuang VTG, Hashimoto M, Nakayama M, Sakuragi M, Enoki Y, Nishi K, Matsumoto K, Seo H, Otagiri M, Yamasaki K.
  Characterization of bovine lactoferrin nanoparticle prepared by desolvation technique.
  Chem Pharm Bull. 68(8): 766-772. (2020)
• Tokuno M, Taguchi K, Yamasaki K, Otagiri M.
  Hepatic cytochrome P450 profiles in hemorrhagic shock model rats after transfusion with stored red blood cells.
  J Pharm Sci. 109(11): 3490-3499. (2020)
• Tokuno M, Taguchi K, Sakai H, Ohtsuki S, Yamasaki K, Otagiri M.
  Assessing cytochrome P450-based drug-drug interactions with Hemoglobin-vesicles, an artificial red blood cell preparation, in healthy rats.
  Drug Metab Pharmacokinet. 35(5): 425-431. (2020)
• Tokuno M, Taguchi K, Sakai H, Ohtsuki S, Yamasaki K, Otagiri M.
  Evaluation of cytochrome P450-based drug metabolism in hemorrhagic shock rats that were transfused with native and an artificial red blood cell preparation, Hemoglobin-vesicles.
  Drug Metab Pharmacokinet. 35(5): 417-424. (2020)
• Hashimoto M, Taguchi K, Imoto S, Yamasaki K, Mitsuya H, Otagiri M.
  Pharmacokinetic properties of orally administered 4′-cyano-2′-deoxyguanosine, a novel nucleoside analog inhibitor of the hepatitis B virus, in viral liver injury model rats.
  Biol Pharm Bull. 43(9): 1426-1429. (2020)
• Yamasaki K, Sakurama K, Nishi K, Watanabe H, Maruyama T, Seo H, Otagiri M, Taguchi K.
  Characterization of the interaction of daptomycin with site II on human serum albumin.
  J Pharm Sci. 109(9): 2919-2924. (2020)
• Okamoto Y, Taguchi K, Imoto S, Chuang VTG, Yamasaki K, Otagiri M.
  Cell uptake and anti-tumor effect of liposomes containing encapsulated paclitaxel-bound albumin against breast cancer cells in 2D and 3D cultured models.
  J Drug Deliv Sci Technol. 55: 101381. (2020)
• Enoki Y, Suzuki N, Ito M, Uchiyama E, Kishi N, Ito C, Kitahiro Y, Sakamoto K, Taguchi K, Yokoyama Y, Kizu J, Matsumoto K.
  Concurrent administration with multivalent metal cation preparations or polycationic polymer preparations inhibits the absorption of raltegravir via its chelation.
  J Pharm Pharmacol. 72(10): 1361-1369. (2020)
• Hashimoto M, Chuang VTG, Ishima Y, Ikeda M, Maruyama T, Yamasaki K, Taguchi K, Otagiri M.
  A safety evaluation study in mice revealed that albumin dimer is safe for medical and pharmaceutical applications.
  BPB reports. 3(2): 87-91. (2020)
• Akahane M, Enoki Y, Saiki R, Hayashi Y, Hiraoka K, Honma K, Itagaki M, Gotoda M, Shinoda K, Hanyu S, Hamamura Y, Miyajima T, Ito C, Taguchi K, Uno S, Uwamino Y, Iketani O, Hasegawa N, Matsumoto K.
  Stability of antimicrobial agents in an elastomeric infusion pump used for outpatient parenteral antimicrobial therapy.
  Int J Infect Dis. 103: 464-468. (2020)
• Osa S, Tashiro S, Igarashi Y, Watabe Y, Liu X, Enoki Y, Taguchi K, Mayumi T, Miyazaki Y, Takesue Y, Matsumoto K.
  Azoles versus conventional amphotericin B for the treatment of candidemia: A meta-analysis of randomized controlled trials.
  J Infect Chemother. 26(11): 1232-1236. (2020)
• Tashiro S, Osa S, Igarashi Y, Watabe Y, Liu X, Enoki Y, Taguchi K, Mayumi T, Miyazaki Y, Takesue Y, Matsumoto K.
  Echinocandins versus non-Echinocandins for the treatment of invasive candidiasis: A meta-analysis of randomized controlled trials.
  J Infect Chemother. 26(11): 1164-1176. (2020)
• Fukunaga M, Kadowaki D, Mori M, Hagiwara S, Narita Y, Saruwatari J, Tanaka R, Watanabe H, Yamasaki K, Taguchi K, Ito H, Maruyama T, Otagiri M, Hirata S.
  In Vivo evaluation of drug dialyzability in a rat model of hemodialysis.
  PLoS One. 15(6): e0233925. (2020)
• Son K, Ueda M, Taguchi K, Maruyama T, Takeoka S, Ito Y.
  Evasion of the accelerated blood clearance phenomenon by polysarcosine coating of liposomes.
  J Control Release. 322: 209-216. (2020)
• Takaya R, Misawa K, Tashiro S, Enoki Y, Taguchi K, Matsumoto K.
  Factorial analysis of Clostridioides Difficile colitis and pseudomembranous colitis using JADER.
  BPB reports. 3(1): 1-6. (2020)
• Furukawa S, Sasao A, Yonemitsu K, Ohtsu Y, Tsutsumi H, Taguchi K, Otagiri M, Nishitani Y.
  Effects of arterial hemorrhage speed on the blood coagulation/fibrinolysis system and hemodynamics in rats.
  Blood Coagul Fibrinolysis. 31(3): 198-206. (2020)
• Yamasaki K, Iohara D, Oyama Y, Nishizaki N, Kawazu S, Nishi K, Kadowaki D, Taguchi K, Otagiri M, Seo H.
  Processing grapefruit juice with γ-cyclodextrin attenuates its inhibitory effect on cytochrome P450 3A activity.
  J Pharm Pharmacol. 72(3): 356-363. (2020)
• Samura M, Hirose N, Kurata T, Ishii J, Nagumo F, Takada K, Koshioka S, Uchida M, Yamamoto S, Inoue J, Enoki Y, Taguchi K, Ishida A, Sekine H, Kunika N, Kunishima H, Matsumoto K.
  Support for fungal infection treatment mediated by pharmacist-led antifungal stewardship activities.
  J Infect Chemother. 26(3): 272-279. (2020)
• Okamoto Y, Taguchi K, Sakuragi M, Imoto S, Yamasaki K, Otagiri M.
  Preparation, characterization, and in vitro/in vivo evaluation of paclitaxel-bound albumin-encapsulated liposomes for the treatment of pancreatic cancer.
  ACS Omega. 4: 8693-8700. (2019)
• Ando G, Taguchi K, Enoki Y, Yokoyama Y, Kizu J, Matsumoto K.
  Evaluation of the expression time of ganciclovir-induced adverse events using JADER and FAERS.
  Biol Pharm Bull. 42(11): 1799-1804. (2019)
• Ito R, Yoshida A, Taguchi K, Enoki Y, Yokoyama Y, Matsumoto K.
  Experimental verification of factors influencing calcium salt formation based on a survey of the development of ceftriaxone-induced gallstone-related disorder.
  J Infect Chemother. 25(12): 972-978. (2019)
• Kuroda Y, Taguchi K, Enoki Y, Matsumoto K, Hori S, Kizu J.
  Age-associated theophylline metabolic activity corresponds to the ratio of 1,3-dimethyluric acid to theophylline in mice.
  Biol Pharm Bull. 42(8): 1423-1427. (2019)
• Yamasaki K, Taguchi K, Nishi K, Otagiri M, Seo H.
  Enhanced dissolution and oral bioavailability of praziquantel by emulsification with human serum albumin followed by spray drying.
  Eur J Pharm Sci. 139: 105064. (2019)
• Hashimoto M, Iketani O, Ichinose N, Enoki Y, Taguchi K, Uno S, Uwamino Y, Hasegawa N, Matsumoto K.
  Evaluation for optimal dosing of vancomycin in patients with different physical types.
  J Infect Chemother. 25(9): 735-737. (2019)
• Matsusaka K, Ishima Y, Hitoshi M, Kinoshita R, Ichimizu S, Taguchi K, Chuang VTG, Nishi K, Yamasaki K, Otagiri M, Watanabe H, Maruyama T.
  α1-acid glycoprotein has the potential to serve as a biomimetic drug delivery carrier for anti-cancer agents.
  J Pharm Sci. 108(11): 3592-3598. (2019)
• Yajima R, Matsumoto K, Yokono K, Watabe Y, Enoki Y, Taguchi K, Ise Y, Katayama S, Kizu J.
  Pharmacokinetic and pharmacodynamic studies of pregabalin suppositories based on pharmacological research.
  J Pharm Pharmacol. 71(5): 746-752. (2019)
• Kimura K, Yamasaki K, Nishi K, Taguchi K, Otagiri M.
  Investigation of anti-tumor effect of doxorubicin-loaded human serum albumin nanoparticles prepared by a desolvation technique.
  Cancer Chemother Pharmacol. 83(6): 1113-1120. (2019)
• Sakurama K, Nishi K, Imoto S, Hashimoto M, Komatsu T, Morita Y, Taguchi K, Otagiri M, Yamasaki K.
  Further evidence regarding the important role of chlorine atoms of aripiprazole on binding to the site II area of human albumin.
  J Pharm Sci. 108(5): 1890-1895. (2019)
• 石渡涼子, 榎木裕紀, 横山雄太, 田口和明, 木津純子, 松元一明.
  ヘパリン類似物質含有製剤の選択に有用な情報構築に関する検討.
  日本老年薬学会雑誌, 2(2): 19-26. (2019)
• Taguchi K, Lu H, Jiang Y, Hung T, Stenzel M.
  Safety of nanoparticles based on albumin–polymer conjugates as a carrier of nucleotides for pancreatic cancer therapy.
  J Mater Chem B. 6: 6278-6287. (2018)
• Taguchi K, Nagao S, Maeda H, Yanagisawa H, Sakai H, Yamasaki K, Wakayama T, Watanabe H, Otagiri M, Maruyama T.
  Biomimetic carbon monoxide delivery based on hemoglobin vesicles ameliorates acute pancreatitis in mice via the regulation of macrophage and neutrophil activity.
  Drug Deliv. 25(1): 1266-1274. (2018)
• Okamoto Y, Taguchi K, Sakuragi M, Imoto S, Yamasaki K, Otagiri M.
  In vivo drug delivery efficiency of albumin-encapsulated liposomes as hydrophobic drug carriers.
  J Drug Deliv Sci Technol. 47: 62-66. (2018)
• Yamasaki K, Nishi K, Anraku M, Taguchi K, Maruyama T, Otagiri M.
  Metal-catalyzed oxidation of human serum albumin does not alter the interactive binding to the two principal drug binding sites.
  Biochem Biophys Rep. 14: 155-160. (2018)
• Hashimoto M, Taguchi K, Ishiguro T, Kohgo S, Imoto S, Yamasaki K, Mitsuya H, Otagiri M.
  Pharmacokinetic properties of a novel inosine analog, 4′-cyano-2′-deoxyinosine, after oral administration in rats.
  PLoS One. 13(6): e0198636. (2018)
• Hashimoto M, Taguchi K, Ishiguro T, Kohgo S, Imoto S, Yamasaki K, Mitsuya H, Otagiri M.
  Pharmacokinetics studies of 4′-cyano-2′-deoxyguanosine, a potent inhibitor of the hepatitis B virus, in rats.
  J Pharm Pharmacol. 70(6): 723-731. (2018)
• Okamoto Y, Taguchi K, Yamasaki K, Sakuragi M, Kuroda S, Otagiri M.
  Albumin-encapsulated liposomes: A novel drug delivery carrier with hydrophobic drugs encapsulated in the inner aqueous core.
  J Pharm Sci. 107(1): 436-445. (2018)
• Sakurama K, Kawai A, Chuang VTG, Kanamori Y, Osa M, Taguchi K, Seo H, Maruyama T, Imoto S, Yamasaki K, Otagiri M.
  Analysis of the binding of aripiprazole to human serum albumin: The importance of a chloro-group in the chemical structure.
  ACS Omega. 3(10): 13790-13797. (2018)
• Igarashi Y, Tashiro S, Enoki Y, Taguchi K, Matsumoto K, Ohge H, Suzuki H, Nakamura A, Mori N, Morinaga Y, Yamagishi Y, Yoshizawa S, Yanagihara K, Mikamo H, Kunishima H.
  Oral vancomycin versus metronidazole for the treatment of Clostridioides difficile infection: Meta-analysis of randomized controlled trials.
  J Infect Chemother. 24(11): 907-914. (2018)
• Muraya N, Kadowaki D, Miyamura S, Kitamura K, Uchimura K, Narita Y, Miyamoto Y, Chuang VTG, Taguchi K, Maruyama T, Otagiri M, Hirata S. Benzbromarone attenuates oxidative stress in gngiotensin II- and salt-induced hypertensive model rats.
  Oxid Med Cell Longev. 2018: 7635274. (2018)
• Kimura K, Yamasaki K, Nakamura H, Haratake M, Taguchi K, Otagiri M.
  Preparation and in vitro analysis of human serum albumin nanoparticles loaded with anthracycline derivatives.
  Chem Pharm Bull. 66(4): 382-390. (2018)
• Minayoshi Y, Maeda H, Yanagisawa H, Hamasaki K, Mizuta Y, Nishida K, Kinoshita R, Enoki Y, Imafuku T, Chuang VTG, Koga T, Fujiwara Y, Takeya M, Sonoda K, Wakayama T, Taguchi K, Ishima Y, Ishida T, Iwakiri Y, Tanaka M, Sasaki Y, Watanabe H, Otagiri M, Maruyama T.
  Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via inducing anti-inflammatory and immunomodulatory actions.
  Drug Deliv. 25(1): 1067-1077. (2018)
• Sakuragi M, Taguchi K, Kusakabe K.
  Structural and biological characterization of Fe₃O₄-loaded spherical and tubular liposomes for use in drug delivery systems.
  Jpn J Appl Phys. 56(5): 055002. (2017)
• Yamasaki K, Hyodo S, Taguchi K, Nishi K, Yamaotsu N, Hirono S, Chuang VTG, Seo H, Maruyama T, Otagiri M.
  Long chain fatty acids alter the interactive binding of ligands to the two principal drug binding sites of human serum albumin.
  PLoS One. 12(6): e0180404. (2017)
• Yamasaki K, Enokida T, Taguchi K, Miyamura S, Kawai A, Miyamoto S, Maruyama T, Seo H, Otagiri M.
  Species differences in the binding of sodium 4-phenylbutyrate to serum albumin.
  J Pharm Sci. 106(9): 2860-2867. (2017)
• Sakuragi M, Zushi T, Seguchi R, Arai T, Taguchi K, Kusakabe K.
  Locational analysis of glutathione in liposomes by using small-angle X-ray scattering.
  Chem Lett. 46(2): 185-187. (2017)
• Yamasaki K, Sato H, Minagoshi S, Kyubun K, Anraku M, Miyamura S, Watanabe H, Taguchi K, Seo H, Maruyama T, Otagiri M.
  The binding of silibinin, the main constituent of silymarin, to Site I on human serum albumin.
  Biol Pharm Bull. 40(3): 310-317. (2017)
• Matsushita S, Nishi K, Iwao Y, Ishima Y, Watanabe H, Taguchi K, Yamasaki K, Maruyama T, Otagiri M.
  Recombinant human serum albumin containing 3 copies of domain I, has significant in vitro antioxidative capacity compared to the wild-type.
  Biol Pharm Bull. 40(10): 1813-1817. (2017)
• Tokuno M, Taguchi K, Yamasaki K, Sakai H, Otagiri M.
  Long-term stored Hemoglobin-vesicles, a cellular type of hemoglobin-based oxygen carrier, has resuscitative effects comparable to that for fresh red blood cells in a rat model with massive hemorrhage without post-transfusion lung injury.
  PLoS One. 11(10): e0165557. (2016)
• Nagao S, Taguchi K, Miyazaki Y, Wakayama T, Chuang VTG, Yamasaki K, Watanabe H, Sakai H, Otagiri M, Maruyama T.
  Evaluation of a new type of nano-sized carbon monoxide donor on treating mice with experimentally induced colitis.
  J Control Release. 234: 49-58. (2016)
• Nagao S, Taguchi K, Sakai H, Yamasaki K, Watanabe H, Otagiri M, Maruyama T.
  Carbon monoxide-bound hemoglobin vesicles ameliorate multiorgan injuries induced by severe acute pancreatitis in mice by their anti-inflammatory and antioxidant properties.
  Int J Nanomedicine. 11: 5611-5620. (2016)
• Anraku M, Iohara D, Wada K, Taguchi K, Maruyama T, Otagiri M, Uekama K, Hirayama F.
  Antioxidant and renoprotective activity of 2-hydroxypropyl-β-cyclodextrin in nephrectomized rats.
  J Pharm Pharmacol. 68(5): 608-614. (2016)
• Enokida T, Yamasaki K, Okamoto Y, Taguchi K, Ishiguro T, Maruyama T, Seo H, Otagiri M.
  Tyrosine 411 and arginine 410 of human serum albumin play an important role in the binding of sodium 4-phenylbutyrate to site II.
  J Pharm Sci. 105(6): 1987-1994. (2016)
• Miyamura S, Imafuku T, Anraku M, Taguchi K, Yamasaki K, Tominaga Y, Maeda H, Ishima Y, Watanabe H, Otagiri M, Maruyama T.
  Comparison of posttranslational modification and the functional impairment of human serum albumin in commercial preparations.
  J Pharm Sci. 105(3): 1043-1049. (2016)
• Yamada K, Yokomaku K, Haruki R, Taguchi K, Nagao S, Maruyama T, Otagiri M, Komatsu T.
  Influence of molecular structure on O₂-binding properties and blood circulation of Hemoglobin‒Albumin clusters.
  PLoS One. 11(2): e0149526. (2016)
• Taguchi K, Hashimoto M, Ogaki S, Watanabe H, Takeoka S, Ikeda Y, Handa M, Otagiri M, Maruyama T.
  Effect of repeated injections of adenosine diphosphate-encapsulated liposomes coated with a fibrinogen γ-chain dodecapeptide developed as a synthetic platelet substitute on accelerated blood clearance in a healthy and an anticancer drug-induced thrombocytopenia rat model.
  J Pharm Sci. 104(9): 3084-3091. (2015)
• Taguchi K, Chuang VTG, Yamasaki K, Urata Y, Tanaka R, Anraku M, Seo H, Kawai K, Maruyama T, Komatsu T, Otagiri M.
  Cross-linked human serum albumin dimer has the potential for use as a plasma-retaining agent for the fatty acid-conjugated antidiabetic drugs.
  J Pharm Pharmacol. 67(2): 255-263. (2015)
• Taguchi K, Nagao S, Yamasaki K, Sakai H, Seo H, Maruyama T, Otagiri M.
  Biological responsiveness and metabolic performance of liposome-encapsulated hemoglobin (Hemoglobin-vesicles) in apolipoprotein E-deficient mice after massive intravenous injection.
  Biol Pharm Bull. 38(10): 1606-1616. (2015)
• Taguchi K, Tokuno M, Yamasaki K, Kadowaki D, Seo H, Otagiri M.
  Establishment of a model of acetaminophen-induced hepatotoxicity in different weekly-aged ICR mice.
  Lab Anim. 49(4): 294-301. (2015)
• Hashimoto M, Taguchi K, Ogaki S, Watanabe H, Kinoshita M, Nishikawa K, Takeoka S, Ikeda Y, Handa M, Otagiri M, Maruyama T.
  Pharmacokinetic properties of single and repeated injection of liposomal platelet substitute in a rat model of red blood cell transfusion-induced dilutional thrombocytopenia.
  J Pharm Sci. 104(11): 3968-3976. (2015)
• Ogaki S, Taguchi K, Maeda H, Watanabe H, Ishima Y, Otagiri M, Maruyama T.
  Kupffer cell inactivation by carbon monoxide bound to red blood cells preserves hepatic cytochrome P450 via anti-oxidant and anti-inflammatory effects exerted through the HMGB1/TLR-4 pathway during resuscitation from hemorrhagic shock.
  Biochem Pharmacol. 97(3): 310-319. (2015)
• Anraku M, Shintomo R, Taguchi K, Kragh-Hansen U, Kai T, Maruyama T, Otagiri M.
  Amino acids of importance for the antioxidant activity of human serum albumin as revealed by recombinant mutants and genetic variants.
  Life Sci. 134: 36-41. (2015)
• Li H, Ohta H, Tahara Y, Nakamura S, Taguchi K, Nakagawa M, Oishi Y, Goto Y, Wada K, Kaga M, Inagaki M, Otagiri M, Yokota H, Shibata S, Sakai H, Okamura K, Yaegashi N.
  Artificial oxygen carriers rescue placental hypoxia and improve fetal development in the rat pre-eclampsia model.
  Sci Rep. 5: 15271. (2015)
• Kadowaki D, Sakaguchi S, Miyamoto Y, Taguchi K, Muraya N, Narita Y, Sato K, Chuang VTG, Maruyama T, Otagiri M, Hirata S.
  Direct radical scavenging activity of benzbromarone provides beneficial antioxidant properties for hyperuricemia treatment.
  Biol Pharm Bull. 38(3): 487-492. (2015)
• Maeda H, Hirata K, Watanabe H, Ishima Y, Chuang VTG, Taguchi K, Inatsu A, Kinoshita M, Tanaka M, Sasaki Y, Otagiri M, Maruyama T.
  Polythiol-containing, recombinant mannosylated-albumin is a superior CD68⁺/CD206⁺ Kupffer cell-targeted nanoantioxidant for treatment of two acute hepatitis models.
  J Pharmacol Exp Ther. 352(2): 244-257. (2015)
• Haruki R, Kimura T, Iwasaki H, Yamada K, Kamiyama I, Kohno M, Taguchi K, Nagao S, Maruyama T, Otagiri M, Komatsu T.
  Safety evaluation of Hemoglobin-Albumin cluster “HemoAct” as a red blood cell substitute.
  Sci Rep. 5: 12778. (2015)
• Taguchi K, Yamasaki K, Maesaki H, Tokuno M, Okazaki S, Moriuchi H, Takeshita K, Otagiri M, Seo H.
  An evaluation of novel biological activity in a crude extract from Hemerocallis fulva L.var. sempervirens Hotta.
  Nat Prod Res. 28(23): 2211-2213. (2014)
• Miyazaki Y, Taguchi K, Sou K, Watanabe H, Ishima Y, Miyakawa T, Mitsuya H, Fukagawa M, Otagiri M, Maruyama T.
  Therapeutic impact of erythropoietin-encapsulated liposomes targeted to bone marrow on renal anemia.
  Mol Pharm. 11(11): 4238-4248. (2014)
• Ogaki S, Taguchi K, Watanabe H, Ishima Y, Otagiri M, Maruyama T.
  Carbon monoxide bound red blood cell resuscitation ameliorate hepatic injury induced by massive hemorrhage and red blood cell resuscitation via hepatic CYP protection in hemorrhagic shock rats.
  J Pharm Sci. 103(7): 2199-2206. (2014)
• Taguchi K, Kouroki M, Ohmura T, Jono H, Endo F, Saito H.
  Carbamazepine-imatinib interaction in a child with chronic myeloid leukemia.
  Pediatr Int. 56(4): e33-36. (2014)
• Nagao S, Taguchi K, Sakai H, Tanaka R, Horinouchi H, Watanabe H, Kobayashi K, Otagiri M, Maruyama T.
  Carbon monoxide-bound hemoglobin-vesicles for the treatment of bleomycin-induced pulmonary fibrosis.
  Biomaterials. 35(24): 6553-6562. (2014)
• Taguchi K, Ohmura T, Ohya Y, Horio M, Furukawa K, Jono H, Inomata Y, Saito H.
  False tacrolimus concentrations measured by antibody-conjugated magnetic immunoassay in liver transplant patient: 2 case reports and literature review.
  Exp Clin Transplant. 12(5): 474-478. (2014)
• Taguchi K, Jono H, Kugimiya-Taguchi T, Nagao S, Su Y, Yamasaki K, Mizuguchi M, Maruyama T, Ando Y, Otagiri M.
  Effect of albumin on transthyretin and amyloidogenic transthyretin Val30Met disposition and tissue deposition in familial amyloidotic polyneuropathy.
  Life Sci. 93(25-26): 1017-1022. (2013)
• Taguchi K, Ujihira H, Watanabe H, Fujiyama A, Doi M, Takeoka S, Ikeda Y, Handa M, Otagiri M, Maruyama T.
  Pharmacokinetic study of adenosine diphosphate-encapsulated liposomes coated with fibrinogen γ-chain dodecapeptide as a synthetic platelet substitute in an anticancer drug-induced thrombocytopenia rat model.
  J Pharm Sci. 102(10): 3852-3859. (2013)
• Taguchi K, Ujihira H, Ogaki S, Watanabe H, Fujiyama A, Doi M, Okamura Y, Takeoka S, Ikeda Y, Handa M, Otagiri M, Maruyama T.
  Pharmacokinetic study of the structural components of adenosine diphosphate-encapsulated liposomes coated with fibrinogen γ-chain dodecapeptide as a synthetic platelet substitute.
  Drug Metab Dispos. 41(8): 1584-1591. (2013)
• Ogaki S, Taguchi K, Watanabe H, Otagiri M, Maruyama T.
  Carbon monoxide-bound red blood cells protect red blood cell transfusion-induced hepatic cytochrome P450 impairment in hemorrhagic-shock rats.
  Drug Metab Dispos. 41(1): 141-148. (2013)
• Taguchi K, Miyakawa T, Ohmura T, Horio M, Anraku Y, Okada T, Mizuta H, Saito H, Kawaguchi T.
  A reduced linezolid dosage maintains favorable efficacy with minimal hematologic toxicity in a methicillin-resistant Staphylococcus aureus-infected patient with renal insufficiency.
  Scand J Infect Dis. 45(1): 77-80. (2013)
• Kaga M, Li H, Ohta H, Taguchi K, Ogaki S, Izumi H, Inagaki M, Tsuchiya S, Okamura K, Otagiri M, Sakai H, Yaegashi N.
  Liposome-encapsulated hemoglobin (hemoglobin-vesicle) is not transferred from mother to fetus at the late stage of pregnancy in the rat model.
  Life Sci. 91(11-12): 420-428. (2012)
• Hassan F, Meduru S, Taguchi K, Kuppusamy ML, Mostafa M, Kuppusamy P, Khan M.
  Carvedilol enhances mesenchymal stem cell therapy for myocardial infarction via inhibition of caspase-3 expression.
  J Pharmacol Exp Ther. 343(1): 62-71. (2012)
• Kadowaki D, Sumikawa S, Arimizu K, Taguchi K, Kitamura K, Ishitsuka Y, Narita Y, Irie T, Chuang VTG, Maruyama T, Otagiri M, Hirata S.
  Effect of acetaminophen on the progression of renal damage in adenine induced renal failure model rats.
  Life Sci. 91(25-26): 1304-1308. (2012)
• Taguchi K, Iwao Y, Watanabe H, Kadowaki D, Sakai H, Kobayashi K, Horinouchi H, Maruyama T, Otagiri M.
  Repeated injection of high doses of hemoglobin-encapsulated liposomes (hemoglobin vesicles) induces accelerated blood clearance in a hemorrhagic shock rat model.
  Drug Metab Dispos. 39(3): 484-489. (2011)
• Taguchi K, Miyasato M, Watanabe H, Sakai H, Tsuchida E, Horinouchi H, Kobayashi K, Maruyama T, Otagiri M.
  Alteration in the pharmacokinetics of hemoglobin-vesicles in a rat model of chronic liver cirrhosis is associated with Kupffer cell phagocyte activity.
  J Pharm Sci. 100(2): 775-783. (2011)
• Taguchi K, Ogaki S, Watanabe H, Kadowaki D, Sakai H, Kobayashi K, Horinouchi H, Maruyama T, Otagiri M.
  Fluid resuscitation with hemoglobin vesicles prevents Escherichia coli growth via complement activation in a hemorrhagic shock rat model.
  J Pharmacol Exp Ther. 337(1): 201-208. (2011)
• Furukawa M, Tanaka R, Chuang VTG, Ishima Y, Taguchi K, Watanabe H, Maruyama T, Otagiri M.
  Human serum albumin-thioredoxin fusion protein with long blood retention property is effective in suppressing lung injury.
  J Control Release. 154(2): 189-195. (2011)
• Minomo A, Ishima Y, Kragh-Hansen U, Chuang VTG, Uchida M, Taguchi K, Watanabe H, Maruyama T, Morioka H, Otagiri M.
  Biological characteristics of two lysines on human serum albumin in the high affinity binding of 4Z,15Z-bilirubin-Ixα revealed by phage display.
  FEBS J. 278(21): 4100-4111. (2011)
• Taguchi K, Urata Y, Anraku M, Watanabe H, Kawai K, Komatsu T, Tsuchida E, Maruyama T, Otagiri M.
  Superior plasma retention of a cross-linked human serum albumin dimer in nephrotic rats as a new type of plasma expander.
  Drug Metab Dispos. 38(12): 2124-2129. (2010)
• Taguchi K, Miyasato M, Ujihira H, Watanabe H, Kadowaki D, Sakai H, Tsuchida E, Horinouchi H, Kobayashi K, Maruyama T, Otagiri M.
  Hepatically-metabolized and -excreted artificial oxygen carrier, hemoglobin vesicles, can be safely used under conditions of hepatic impairment.
  Toxicol Appl Pharmacol. 248(3): 234-241. (2010)
• Mady FM, Abou-Taleb AE, Khaled KA, Yamasaki K, Iohara D, Taguchi K, Anraku M, Hirayama F, Uekama K, Otagiri M.
  Evaluation of carboxymethyl-beta-cyclodextrin with acid function: improvement of chemical stability, oral bioavailability and bitter taste of famotidine.
  Int J Pharm. 397(1-2): 1-8. (2010)
• Taguchi K, Urata Y, Anraku M, Watanabe H, Kadowaki D, Sakai H, Horinouchi H, Kobayashi K, Tsuchida E, Maruyama T, Otagiri M.
  Hemoglobin vesicles, polyethylene glycol (PEG)ylated liposomes developed as a red blood cell substitute, do not induce the accelerated blood clearance phenomenon in mice.
  Drug Metab Dispos. 37(11): 2197-2203. (2009)
• Taguchi K, Urata Y, Anraku M, Maruyama T, Watanabe H, Sakai H, Horinouchi H, Kobayashi K, Tsuchida E, Kai T, Otagiri M.
  Pharmacokinetic study of enclosed hemoglobin and outer lipid component after the administration of hemoglobin vesicles as an artificial oxygen carrier.
  Drug Metab Dispos. 37(7): 1456-1463. (2009)
• Taguchi K, Maruyama T, Iwao Y, Sakai H, Kobayashi K, Horinouchi H, Tsuchida E, Kai T, Otagiri M.
  Pharmacokinetics of single and repeated injection of hemoglobin-vesicles in hemorrhagic shock rat model.
  J Control Release. 136(3): 232-239. (2009)
• Kadowaki D, Anraku M, Tasaki Y, Taguchi K, Shimoishi K, Seo H, Hirata S, Maruyama T, Otagiri M.
  Evaluation for antioxidant and renoprotective activity of olmesartan using nephrectomy rats.
  Biol Pharm Bull. 32(12): 2041-2045. (2009)
• Shimoishi K, Anraku M, Kitamura K, Tasaki Y, Taguchi K, Hashimoto M, Fukunaga E, Maruyama T, Otagiri M.
  An oral adsorbent, AST-120 protects against the progression of oxidative stress by reducing the accumulation of indoxyl sulfate in the systemic circulation in renal failure.
  Pharm Res. 24(7): 1283-1289. (2007)

（総説論文）

• Target therapeutic ranges of anti-MRSA drugs, linezolid, tedizolid and daptomycin, and the necessity of TDM.
  Matsumoto K, Samura M, Tashiro S, Shishido S, Saiki R, Takemura W, Misawa K, Liu X, Enoki Y, Taguchi K.
  Biol Pharm Bull. 45(7): 824-833. (2022)
• Taguchi K, Okamoto Y, Matsumoto K, Otagiri M, Chuang VTG.
  When albumin meets liposomes: A feasible drug carrier for biomedical applications.
  Pharmaceuticals. 14(4): 296. (2021)
• 田口和明, 小田切優樹, 松元一明.
  一酸化炭素製剤開発の最前線.
  人工血液, 29(1): 57-63. (2021)
• 田口和明.
  赤血球バイオミメティックによる生理活性ガス送達戦略と難治性疾患治療への展開.
  Drug Delivery System. 34(4): 300-306. (2021)
• Taguchi K.
  Pharmaceutical technology innovation strategy based on the function of blood transport proteins as DDS carriers for the treatment of intractable disorders and cancer.
  Biol Pharm Bull. 43(12): 1815-1822. (2020)
• Taguchi K, Maruyama T, Otagiri M.
  Use of hemoglobin for delivering exogenous carbon monoxide in medicinal applications.
  Curr Med Chem. 27(18): 2949-2963. (2020)
• 田口和明, 松元一明, 丸山徹, 小田切優樹.
  ヘモグロビンの生理活性ガス運搬能を利用した創薬戦略.
  薬学雑誌, 140(2): 141-146. (2020)
• Taguchi K, Yamasaki K, Sakai H, Maruyama T, Otagiri M.
  The use of Hemoglobin vesicles for delivering medicinal gas for the treatment of intractable disorders.
  J Pharm Sci. 106(9): 2392-2400. (2017)
• 田口和明.
  細胞型人工赤血球の動態特性解析に基づく安全性評価と医療ガスデリバリーへの応用.
  薬学雑誌, 138(11): 1381-1389. (2018)
• Taguchi K, Yamasaki K, Maruyama T, Otagiri M.
  Comparison of the pharmacokinetic properties of hemoglobin-based oxygen carriers.
  J Funct Biomater. 8(1): E11. (2017)
• Taguchi K, Yamasaki K, Seo H, Otagiri M.
  Potential use of biological proteins for liver failure therapy.
  Pharmaceutics. 7(3): 255-274. (2015)
• 田口和明, 猿渡淳二, 平田憲史郎, 丸山徹.
  TDMの落とし穴～偽陽性と偽陰性～.
  医療薬学, 41(4): 215-222. (2015)
• Taguchi K, Chuang VTG, Maruyama T, Otagiri M.
  Pharmaceutical aspects of the recombinant human serum albumin dimer: structural characteristics, biological properties, and medical applications.
  J Pharm Sci. 101(9): 3033-3046. (2012)
• Taguchi K, Maruyama T, Otagiri M.
  Pharmacokinetic properties of hemoglobin vesicles as a substitute for red blood cells.
  Drug Metab Rev. 43(3): 362-373. (2011)
• 田口和明, 丸山徹, 小田切優樹.
  ヘモグロビン小胞体 (HbV) の体内動態に関する検討.
  人工血液, 17: 169-178. (2009)